Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Differences in rate and trajectory of TDP-43-associated neurodegeneration in brains with and without frontotemporal lobar degeneration
Aging and Dementia
S20 - Aging and Dementia 2 (2:12 PM-2:24 PM)
007

TDP-43, a primary pathologic substrate in tau-negative FTLD, is often found in the brains of elderly individuals without FTLD and is a key player in the process of neurodegeneration. Non-FTLD TDP-43 inclusions are not homogeneous and can be divided into two morphologic types: type-α and neurofibrillary tangle-associated type-β. Patterns of TDP-43-associated brain atrophy in presence/absence of FTLD or by morphologic subtype are unknown.

To compare rates and trajectories of TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration (FTLD) and to explore whether neurodegeneration also varies by TDP-43 morphologic type.

In this longitudinal retrospective study of 295 autopsied cases with 2541 MRI scans spanning over decade, we used a Bayesian hierarchical linear model to quantify similarities and differences between non-FTLD TDP-43 (type-α/type-β) and FTLD-TDP (n=68) in regional volume at various timepoints before death and annualized rate of atrophy. Since Alzheimer’s disease (AD) is a frequent co-pathology in non-FTLD TDP-43, we further divided types α/β based on presence/absence of intermediate-high likelihood AD: AD-TDP type-β (n=90), AD-TDP type α (n=104), and Pure-TDP(n=31). This study is funded by NIH grants: R01-AG037491-11, P30-AG062677, U01-AG006786, R35-AG11378, R01-AG041851.

FTLD-TDP was associated with faster atrophy rates in the hippocampus, inferior temporal (IT) and middle frontal cortices, with IT lobe being the region distinguishing FTLD-TDP from non-FTLD groups. The atrophy rate in the frontal lobe was modulated by age with younger FTLD-TDP having the fastest rates. In older FTLD-TDP patients, hippocampus and IT lobe are the main targets for neurodegeneration. Pure-TDP was associated with slowest rates and less atrophy in all brain regions.

There are differences and similarities in longitudinal brain volume loss between FTLD-TDP and non-FTLD TDP-43. Within FTLD-TDP age plays a role in which brain regions are the most affected. Brain atrophy regional rates also vary by non-FTLD TDP-43 type.

 

 

Authors/Disclosures
Marina Buciuc, MD (MUSC)
PRESENTER
Dr. Buciuc has nothing to disclose.
No disclosure on file
Nirubol Tosakulwong No disclosure on file
Melissa Murray, PhD (Mayo Clinic) Dr. Murray has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Avid Radiopharmaceuticals. The institution of Dr. Murray has received research support from National Institute on Aging. The institution of Dr. Murray has received research support from Alzheimer's Association. The institution of Dr. Murray has received research support from Chan Zuckerberg Initiative.
No disclosure on file
Matthew Senjem (Mayo Clinic) Matthew Senjem has received stock or an ownership interest from Align Technology, Inc.. Matthew Senjem has received stock or an ownership interest from Inovio Biomedical Corp.. Matthew Senjem has received stock or an ownership interest from Johnson & Johnson. Matthew Senjem has received stock or an ownership interest from Mesa Laboratories, Inc.. Matthew Senjem has received stock or an ownership interest from Nvidia Inc.. Matthew Senjem has received stock or an ownership interest from LHC Group, Inc.. Matthew Senjem has received stock or an ownership interest from Natus Medical Incorporated. Matthew Senjem has received stock or an ownership interest from Varex Imaging Corporation. Matthew Senjem has received personal compensation in the range of $100,000-$499,999 for serving as a IT Technical Specialist II with Mayo Clinic.
No disclosure on file
David S. Knopman, MD, FAAN (Mayo Clinic) Dr. Knopman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DIAN TU study. The institution of Dr. Knopman has received research support from NIH.
Bradley F. Boeve, MD, FAAN (Mayo Clinic) Dr. Boeve has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Rainwater Charitable Foundation. The institution of Dr. Boeve has received research support from Alector. The institution of Dr. Boeve has received research support from EIP Pharma. The institution of Dr. Boeve has received research support from Transposon. The institution of Dr. Boeve has received research support from Cognition Therapeutics. Dr. Boeve has received publishing royalties from a publication relating to health care.
Ronald C. Petersen, MD, PhD, FAAN (Mayo Clinic) Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Nestle. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co.. Dr. Petersen has received personal compensation in the range of $0-$499 for serving as a Consultant for Eisai, Inc.. Dr. Petersen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novo Nordisk. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has received publishing royalties from a publication relating to health care. Dr. Petersen has a non-compensated relationship as a Board of Directors with American Brain Foundation that is relevant to AAN interests or activities.
Joseph E. Parisi, MD (Mayo Clinic) Dr. Parisi has nothing to disclose.
Ross Reichard No disclosure on file
Dennis W. Dickson, MD (Mayo Clinic) Dr. Dickson has nothing to disclose.
Clifford R. Jack, Jr., MD (Mayo Clinic) The institution of Dr. Jack has received research support from NIH. The institution of Dr. Jack has received research support from Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic.
Jennifer Whitwell, PhD (Mayo Clinic) Dr. Whitwell has nothing to disclose.
Keith A. Josephs, Jr., MD, FAAN (Mayo Clinic) Dr. Josephs has nothing to disclose.